JP6524221B2 - Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物 - Google Patents

Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物 Download PDF

Info

Publication number
JP6524221B2
JP6524221B2 JP2017519685A JP2017519685A JP6524221B2 JP 6524221 B2 JP6524221 B2 JP 6524221B2 JP 2017519685 A JP2017519685 A JP 2017519685A JP 2017519685 A JP2017519685 A JP 2017519685A JP 6524221 B2 JP6524221 B2 JP 6524221B2
Authority
JP
Japan
Prior art keywords
methyl
ylamino
acrylamide
pyrazol
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017519685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530999A (ja
JP2017530999A5 (enExample
Inventor
ソ、ピョン−チュル
デヴィダス サルガオンカー、パレッシュ
デヴィダス サルガオンカー、パレッシュ
イ、チェキョ
スン コ、チョン
スン コ、チョン
ソン、ホ−チュン
ヨン イ、イン
ヨン イ、イン
イ、チェサン
シク チョン、トン
シク チョン、トン
キム、チョン−ホ
キム、ソ−ウォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55654993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6524221(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of JP2017530999A publication Critical patent/JP2017530999A/ja
Publication of JP2017530999A5 publication Critical patent/JP2017530999A5/ja
Application granted granted Critical
Publication of JP6524221B2 publication Critical patent/JP6524221B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quick-Acting Or Multi-Walled Pipe Joints (AREA)
JP2017519685A 2014-10-13 2015-10-13 Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物 Active JP6524221B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462063394P 2014-10-13 2014-10-13
US62/063,394 2014-10-13
PCT/KR2015/010784 WO2016060443A2 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019085608A Division JP6754864B2 (ja) 2014-10-13 2019-04-26 Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物

Publications (3)

Publication Number Publication Date
JP2017530999A JP2017530999A (ja) 2017-10-19
JP2017530999A5 JP2017530999A5 (enExample) 2018-04-05
JP6524221B2 true JP6524221B2 (ja) 2019-06-05

Family

ID=55654993

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017519685A Active JP6524221B2 (ja) 2014-10-13 2015-10-13 Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物
JP2019085608A Active JP6754864B2 (ja) 2014-10-13 2019-04-26 Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物
JP2020141205A Withdrawn JP2020196740A (ja) 2014-10-13 2020-08-24 Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019085608A Active JP6754864B2 (ja) 2014-10-13 2019-04-26 Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物
JP2020141205A Withdrawn JP2020196740A (ja) 2014-10-13 2020-08-24 Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物

Country Status (30)

Country Link
US (2) US9593098B2 (enExample)
EP (4) EP3207035B1 (enExample)
JP (3) JP6524221B2 (enExample)
KR (5) KR102662358B1 (enExample)
CN (2) CN111686110B (enExample)
AU (1) AU2015331166B2 (enExample)
BR (1) BR112017007769B1 (enExample)
CA (1) CA2962914C (enExample)
CY (2) CY1122737T1 (enExample)
DK (3) DK3207035T3 (enExample)
ES (3) ES2879474T3 (enExample)
FI (3) FI4421069T3 (enExample)
FR (1) FR25C1021I1 (enExample)
HR (3) HRP20250213T1 (enExample)
HU (4) HUE054848T2 (enExample)
LT (4) LT3207035T (enExample)
MX (3) MX385942B (enExample)
NL (1) NL301329I2 (enExample)
NO (1) NO2025025I1 (enExample)
NZ (1) NZ730012A (enExample)
PH (1) PH12017500488A1 (enExample)
PL (3) PL3604294T3 (enExample)
PT (3) PT3929190T (enExample)
RS (3) RS66529B1 (enExample)
RU (1) RU2727700C2 (enExample)
SG (1) SG11201701960XA (enExample)
SI (3) SI3207035T1 (enExample)
SM (3) SMT202500069T1 (enExample)
TW (2) TWI664173B (enExample)
WO (1) WO2016060443A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019163277A (ja) * 2014-10-13 2019-09-26 ユハン コーポレーションＹｕｈａｎ Ｃｏｒｐｏｒａｔｉｏｎ Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
US10435388B2 (en) 2016-01-07 2019-10-08 Cs Pharmatech Limited Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
SG11201809751XA (en) 2016-05-26 2018-12-28 Zeno Royalties & Milestones Llc Egfr inhibitor compounds
KR102030886B1 (ko) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
ES2963921T3 (es) * 2017-06-13 2024-04-03 Beijing Avlstone Biotechnology Co Ltd Compuestos de aminopirimidina, su método de preparación y uso de los mismos
SG11201913556SA (en) * 2017-07-28 2020-02-27 Yuhan Corp Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
EP3658553B1 (en) * 2017-07-28 2022-06-15 Yuhan Corporation Intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same
KR102688084B1 (ko) * 2017-07-28 2024-07-24 주식회사유한양행 아미노피리미딘 유도체의 개선된 제조방법
WO2019042187A1 (zh) * 2017-08-30 2019-03-07 深圳市塔吉瑞生物医药有限公司 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
CN108017633A (zh) * 2018-01-30 2018-05-11 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
CN108047207A (zh) * 2018-01-30 2018-05-18 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用
AU2019340366B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
EP3885346A4 (en) * 2018-12-21 2022-01-12 Shenzhen TargetRx, Inc. Aminopyrimidine compound used for inhibiting activity of protein kinase
CN113840842A (zh) 2019-02-26 2021-12-24 詹森生物科技公司 利用双特异性抗EGFR/c-Met抗体的联合疗法和患者分层
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
KR102318875B1 (ko) 2019-03-19 2021-11-01 보로노이 주식회사 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물
CN111747950B (zh) 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
AU2020250832A1 (en) 2019-03-29 2021-11-11 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
EA202193117A1 (ru) * 2019-05-14 2022-02-11 Янссен Байотек, Инк. КОМБИНИРОВАННЫЕ ТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К EGFR/c-MET И 3-ГО ПОКОЛЕНИЯ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ EGFR
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
CN110128354A (zh) * 2019-06-20 2019-08-16 大连大学 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法
KR20210032093A (ko) 2019-09-16 2021-03-24 제이투에이치바이오텍 (주) Ｅｇｆｒ 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JP2023510426A (ja) 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
KR20210152312A (ko) * 2020-06-08 2021-12-15 주식회사 종근당 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물
AU2021339962A1 (en) 2020-09-14 2023-05-25 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
TWI867047B (zh) * 2020-09-18 2024-12-21 南韓商沃若諾伊公司 雜芳基衍生物、其製備方法、及含彼作為活性成份之藥學組成物
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
WO2022131741A1 (ko) * 2020-12-14 2022-06-23 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
US20240262815A1 (en) * 2021-05-07 2024-08-08 Voronoi Inc. Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient
IL298474A (en) * 2021-05-17 2023-01-01 Voronoibio Inc Compounds of heteroaryl derivatives and uses thereof
WO2022253261A1 (zh) 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
KR102685187B1 (ko) 2021-10-15 2024-07-16 제이투에이치바이오텍 (주) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
IL315848A (en) 2022-03-31 2024-11-01 Astrazeneca Ab Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
PE20250268A1 (es) 2022-04-28 2025-01-29 Astrazeneca Ab Compuestos heteroaromaticos biciclicos condensados y uso en el tratamiento del cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
KR20250029133A (ko) 2022-06-27 2025-03-04 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
WO2024096624A1 (en) * 2022-11-03 2024-05-10 Voronoi Inc. Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor
CN116655600B (zh) * 2023-05-23 2025-08-22 江南大学 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
WO2025017409A1 (en) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
WO2026009146A1 (en) 2024-07-01 2026-01-08 Hetero Labs Limited Benzimidazole compounds as egfr inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280515A1 (en) 1997-03-11 1998-09-17 E.I. Du Pont De Nemours And Company Heteroaryl azole herbicides
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
ES2375491T3 (es) 2000-12-21 2012-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol útiles como agentes inhibidores de las prote�?na-quinasas.
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
PL369259A1 (en) 2001-11-01 2005-04-18 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
WO2004048343A1 (en) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
JP4428565B2 (ja) 2004-10-05 2010-03-10 東京エレクトロン株式会社 処理液塗布装置
WO2006044457A1 (en) 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20070072894A1 (en) 2005-03-24 2007-03-29 Kempf J V Synthesis of pyrroloquinoline quinone (PQQ)
JP5007029B2 (ja) 2005-07-13 2012-08-22 Ｎｔｎ株式会社 グリース組成物および該グリース封入転がり軸受
BRPI0615270A2 (pt) 2005-08-25 2009-08-04 Hoffmann La Roche pirazol fundido como inibidores de p38 map cinase
JP2007117465A (ja) 2005-10-28 2007-05-17 Sharp Corp 集塵器およびそれを備えた電気掃除機
WO2007111471A1 (en) 2006-03-29 2007-10-04 Ktfreetel Co., Ltd. Digital device and method for providing additional service by using the same
EP2001480A4 (en) 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
AU2007238897A1 (en) 2006-04-12 2007-10-25 Wyeth Anilino-pyrimidine phenyl and benzothiophene analogs
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
TWI458721B (zh) * 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
SG10201407453TA (en) * 2009-11-13 2014-12-30 Genosco Kinase inhibitors
JP5980236B2 (ja) 2011-02-25 2016-08-31 ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ ジアミノピリミジン誘導体及びその製造方法
KR101410902B1 (ko) 2011-07-27 2014-06-20 아스트라제네카 아베 암 치료에 유용한 egfr 조절물질로서 2-(2,4,5-치환된-아닐리노)피리미딘 유도체
KR101944914B1 (ko) * 2012-01-20 2019-02-07 제노스코 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도
WO2014040555A1 (zh) * 2012-09-12 2014-03-20 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3036231B1 (en) * 2013-08-22 2020-02-26 Jubilant Biosys Ltd. Substituted pyrimidine compounds, compositions and medicinal applications thereof
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN111875585B (zh) 2014-06-12 2023-06-23 上海艾力斯医药科技股份有限公司 一类激酶抑制剂
BR112016029662B1 (pt) 2014-06-19 2023-10-24 Takeda Pharmaceutical Company Limited COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO
DK3207035T3 (da) * 2014-10-13 2020-01-27 Yuhan Corp Forbindelser og sammensætninger til modulering af egfr- mutantkinaseaktiviteter
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019163277A (ja) * 2014-10-13 2019-09-26 ユハン コーポレーションＹｕｈａｎ Ｃｏｒｐｏｒａｔｉｏｎ Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物
USRE50528E1 (en) 2014-10-13 2025-08-12 Yuhan Corporation Compounds and compositions for modulating EGFR mutant kinase activities

Also Published As

Publication number Publication date
HUE070874T2 (hu) 2025-07-28
DK3929190T3 (da) 2025-02-24
HRP20200201T1 (hr) 2020-05-15
PT3604294T (pt) 2021-07-29
LT3604294T (lt) 2021-07-26
SMT202000059T1 (it) 2020-03-13
FR25C1021I1 (fr) 2025-08-01
SI3207035T1 (sl) 2020-04-30
KR20240074820A (ko) 2024-05-28
FI4421069T3 (fi) 2026-01-21
KR20230010836A (ko) 2023-01-19
RU2727700C2 (ru) 2020-07-23
SG11201701960XA (en) 2017-04-27
EP4421069A1 (en) 2024-08-28
CN106795144B (zh) 2020-06-16
EP3207035A4 (en) 2018-03-14
KR102073854B1 (ko) 2020-02-05
PT3929190T (pt) 2025-02-19
EP3604294A1 (en) 2020-02-05
HRP20250213T1 (hr) 2025-04-25
SMT202100266T1 (it) 2021-07-12
JP2019163277A (ja) 2019-09-26
KR20170066650A (ko) 2017-06-14
TW201938553A (zh) 2019-10-01
NO2025025I1 (no) 2025-06-05
JP6754864B2 (ja) 2020-09-16
ES2770058T3 (es) 2020-06-30
PL3207035T3 (pl) 2020-06-01
US9593098B2 (en) 2017-03-14
LT3207035T (lt) 2020-02-25
TWI730331B (zh) 2021-06-11
LTPA2025522I1 (enExample) 2025-06-25
FIC20250023I1 (fi) 2025-06-06
KR20200014944A (ko) 2020-02-11
EP3207035B1 (en) 2019-11-20
HUS2500023I1 (hu) 2025-06-28
MX2020002168A (es) 2021-09-07
BR112017007769A2 (pt) 2018-01-16
WO2016060443A2 (en) 2016-04-21
RS61865B1 (sr) 2021-06-30
MX2021010761A (es) 2022-06-09
EP3207035A2 (en) 2017-08-23
HUE048006T2 (hu) 2020-05-28
BR112017007769B1 (pt) 2023-10-10
CN106795144A (zh) 2017-05-31
EP3604294B1 (en) 2021-05-05
DK3207035T3 (da) 2020-01-27
KR102487451B1 (ko) 2023-01-11
DK3604294T3 (da) 2021-06-28
WO2016060443A3 (en) 2016-06-23
NL301329I2 (nl) 2025-09-09
RU2017116598A3 (enExample) 2018-11-21
CN111686110B (zh) 2023-06-16
HUE054848T2 (hu) 2021-09-28
ES3009926T3 (en) 2025-03-31
KR20210011068A (ko) 2021-01-29
CY1122737T1 (el) 2021-03-12
EP4421069B1 (en) 2025-12-10
EP3929190A1 (en) 2021-12-29
LT3929190T (lt) 2025-02-25
SMT202500069T1 (it) 2025-03-12
JP2017530999A (ja) 2017-10-19
HRP20210949T1 (hr) 2021-09-03
RU2017116598A (ru) 2018-11-21
PL3604294T3 (pl) 2021-11-02
MX2017003181A (es) 2017-07-20
PH12017500488A1 (en) 2017-07-31
NZ730012A (en) 2019-06-28
KR102208775B1 (ko) 2021-01-28
CA2962914A1 (en) 2016-04-21
RS59900B1 (sr) 2020-03-31
KR102662358B1 (ko) 2024-04-30
RU2020123547A (ru) 2020-08-18
ES2879474T3 (es) 2021-11-22
TW201619150A (zh) 2016-06-01
SI3604294T1 (sl) 2021-08-31
PL3929190T3 (pl) 2025-06-09
TWI664173B (zh) 2019-07-01
MX385942B (es) 2025-03-18
CA2962914C (en) 2018-10-23
CY1124359T1 (el) 2022-07-22
PT3207035T (pt) 2020-02-19
FI3929190T3 (fi) 2025-02-28
AU2015331166B2 (en) 2018-04-26
SI3929190T1 (sl) 2025-04-30
RS66529B1 (sr) 2025-03-31
CN111686110A (zh) 2020-09-22
JP2020196740A (ja) 2020-12-10
EP3929190B1 (en) 2024-12-25
US20160102076A1 (en) 2016-04-14
USRE50528E1 (en) 2025-08-12
AU2015331166A1 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
USRE50528E1 (en) Compounds and compositions for modulating EGFR mutant kinase activities
RU2838180C1 (ru) Соединения и композиции для модуляции киназной активности мутантов egfr
RU2822389C2 (ru) Соединения и композиции для модуляции киназной активности мутантов egfr
HK40109469A (en) Compounds and compositions for modulating egfr mutant kinase activities
HK40037313B (en) Compounds and compositions for modulating egfr mutant kinase activities
HK40037313A (en) Compounds and compositions for modulating egfr mutant kinase activities
HK1236928A1 (en) Compounds and compositions for modulating egfr mutant kinase activities
BR122023014950B1 (pt) Compostos derivados de aminopirimidina, composição farmacêutica que compreende os ditos compostos e uso terapêutico dos mesmos
HK1236928B (zh) 用於调节egfr突变体激酶活性的化合物和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170419

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190426

R150 Certificate of patent or registration of utility model

Ref document number: 6524221

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250